Autres langues Aprea Therapeutics, Inc.

Actions

APRE

US03836J2015

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 24/04/2024			Varia. 5j.	Varia. 1 janv.
5,17 ^USD	-3,72 %		-9,77 %	+10,00 %

10/04	Aprea Therapeutics, Inc. annonce des présentations sur son inhibiteur de Wee1 de nouvelle génération, Apr-1051, et sur un nouvel inhibiteur macrocyclique d'ATR, ATRN-119, lors de la réunion annuelle 2024 de l'AACR	CI
27/03	APREA THERAPEUTICS, INC. : Wedbush maintient sa recommandation à l'achat	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Aprea Therapeutics, Inc. Announces Presentations on Its Next Generation Wee1 Inhibitor, Apr-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, At AACR Annual Meeting 2024	10/04
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024	10/04
Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading	26/03
Aprea Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	26/03
Aprea Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update	26/03
Aprea Therapeutics Receives FDA Approval of the IND Application for the Drug Candidate Apr-1051	14/03
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million	11/03
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers	11/03
Aprea Therapeutics, Inc. Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers	11/03
Aprea Therapeutics, Inc. announced that it expects to receive $16.000005 million in funding from Exome Asset Management LLC, Stonepine Capital Management LLC, Nantahala Capital Management, LLC, Dafna Capital Management, LLC and other company insiders	11/03
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024	05/03
Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor	06/02
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024	30/01
Sector Update: Health Care Stocks Stronger Late Afternoon	26/01
Aprea Therapeutics Files $150 Million Mixed Shelf; Shares Fall	26/01
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024	04/01
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024	04/01
Aprea Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update	09/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Aprea Therapeutics, Inc.

Actions

APRE

US03836J2015

Autres langues

Filtres